Frederick T. Fraunfelder Lecture with Noriko Koizumi, M.D., Ph.D.

May 18, 2021
5:30 p.m. to 7 p.m.

The lecture will go from 5:30 - 6:30 p.m., followed by a 30 minutes of Q&A with Dr. Koizumi.

When it's time, join your Webex meeting here.
Join Meeting:
Meeting password: yRine8PCY75 

Phone (audio only):
1-206-207-1700 US
1-503-907-9144 Portland, OR
Meeting number (access code): 120 893 5117
Additional call-in numbers:

Mobile phone (one-touch):

Contact Information

Speaker bio

Noriko Koizumi, MD, PhD

Dr. Noriko Koizumi, a clinician scientist, is currently Chair and Professor of the Tissue Engineering Laboratory at the Department of Biomedical Engineering, Doshisha University, Kyoto, Japan. She also holds senior academic appointments in the Ophthalmology Departments of Kyoto Prefectural University of Medicine and Kyoto University where she carries out her clinical duties.

Her current and recent research interests focus on the development of new translational treatments for corneal endothelial dysfunctions such as Fuchs endothelial corneal dystrophy and bullous keratopathy, and her laboratory are influential and active internationally in the cultivation of human corneal endothelial cells for surgical use and fundamental research activities.

To date, Dr. Koizumi has written over 120 research articles and 6 book chapters. She is a recipient of the 2004 Daiwa Adrain Prize for Excellence in Japan-UK research, the 2006 Erwin von Baelz Prize, the 2012 ARVO Foundation/Pfizer Ophthalmics/Carl Camras Translational Research Award, and the 2017 AAO Achievement Award. She served as an ARVO Program Committee Member in the Cornea Section between 2016 and 2019. She has serves as the Editorial Board Member of Investigative Ophthalmology & Visual Science since 2018.

Learning objectives

Participants will be able to:

  1. Recognize the concept of cell-based therapy for corneal endothelial dysfunction using cultivated corneal endothelial cells with Rho kinase inhibitor
  2. Understand five year results of First-in-Human clinical study of cell-injection therapy
  3. Recognize future therapeutic modality for corneal endothelial dysfunction